Media coverage about Versartis (NASDAQ:VSAR) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Versartis earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.775433731769 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern’s rankings:
- Cantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price Target (americanbankingnews.com)
- Versartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic Transactions (streetinsider.com)
- Versartis : reports 3Q loss (4-traders.com)
- Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update (finance.yahoo.com)
- Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions (finance.yahoo.com)
Several brokerages have commented on VSAR. BidaskClub lowered shares of Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 target price on shares of Versartis in a research report on Friday, September 8th. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 target price (down from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Morgan Stanley restated an “equal weight” rating and set a $4.00 target price (up from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Finally, Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. Versartis currently has an average rating of “Hold” and an average price target of $7.22.
Versartis (NASDAQ VSAR) opened at 1.80 on Wednesday. Versartis has a 1-year low of $1.70 and a 1-year high of $24.00. The firm’s market cap is $64.04 million. The stock’s 50 day moving average price is $6.27 and its 200 day moving average price is $14.79.
Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same quarter last year, the company earned ($0.92) earnings per share. Equities research analysts predict that Versartis will post ($3.86) EPS for the current year.
In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Versartis (VSAR) Given Daily News Sentiment Score of 0.01” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/01/versartis-vsar-given-daily-news-sentiment-score-of-0-01.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.